The rising incidence of @entity64 , @entity712 ( @entity712 ) and @entity454 ( @entity454 ) has signalled a need to increase awareness, treatment and control of @entity101 . There continues to be a need for effective antihypertensive medications since @entity101 is a major precursor to various forms of @entity65 . The renin-angiotensin (AT) @entity1369 system (RAAS) is a key component to the development of @entity101 and can be one target of drug therapy. Angotensin II (ATII) receptor blockers (ARBs) are the most recent class of agents available to treat @entity101 , which work by by inhibiting ATII at the receptor level. Currently, national consensus guidelines recommend that ARBs should be reserved for @entity101 @entity1 who cannot tolerate @entity1289 ( @entity1289 ) inhibitors (ACEIs). ARBs, however, are moving to the forefront of therapy with a promising role in the area of renoprotection and @entity712 . Recent trials such as the The Renoprotective Effect of the @entity7774 -Receptor Antagonist @entity7056 in @entity1 with @entity8 Due to @entity2175 Trial (IDNT), the Effect of @entity7056 on the Development of @entity2316 in @entity1 with @entity2175 (IRMA2), and The Effects of @entity9886 on Renal and Cardiovascular Outcomes in @entity1 with @entity2175 and @entity8 (RENAAL) study have demonstrated the renoprotective effects of ARBs in @entity1 with @entity164 2 @entity6 . The Valsartan Heart Failure Trial (Val-HeFT) adds to the growing body of evidence that ARBs may improve morbidity and mortality in @entity712 @entity1 . As a class, ARBs are well tolerated and have a lower incidence of cough and @entity113 compared to ACEIs. This article reviews the differences among the ARBs, existing efficacy data in @entity101 , and explores the role of ARBs in @entity712 and @entity8 .

Angiotensin II receptor blockers for the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2175 :: ('MESH:D003924', 'Disease') :: ['Type 2 Diabetes'] @entity8 :: ('MESH:D007674', 'Disease') :: ['Nephropathy', 'renal disease'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure', 'CHF'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'hypertensive'] @entity1369 :: ('MESH:D000450', 'Chemical') :: ['aldosterone'] @entity1289 :: ('1636', 'Gene') :: ['angiotensin converting enzyme', 'ACE'] @entity7774 :: ('MESH:D000809', 'Chemical') :: ['Angiotensin'] @entity2316 :: ('MESH:D003928', 'Disease') :: ['Diabetic Nephropathy'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity7056 :: ('MESH:C081309', 'Chemical') :: ['Irbesartan'] @entity9886 :: ('MESH:D019808', 'Chemical') :: ['Losartan'] @entity164 :: ('MESH:D017827', 'Disease') :: ['Type'] @entity113 :: ('MESH:D000799', 'Disease') :: ['angioedema'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity454 :: ('MESH:D007676', 'Disease') :: ['ESRD', 'end stage renal disease']
@entity101 :: (MESH:D006973,Disease) :: ['hypertension']
